葡萄糖和GLP-1受体双重激素素对肥胖的治疗:一个随机,双盲,安慰剂控制,剂量检测的第二阶段试验
Carel W le Roux1, Oren Steen2, Kathryn J Lucas3
1Diabetes Complications Research Centre, University College Dublin, Dublin, Ireland.
The lancet. Diabetes & endocrinology
|February 8, 2024
概括
苏尔沃杜提德是一种双重葡萄糖和GLP-1受体激动剂,在肥胖的成年人中有效降低了体重. 这项研究证明了剂量依赖的体重减轻和研究药物的良好耐受性.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 药理学 药理学是指药理学的学科.
- 临床研究是临床研究.
背景情况:
- 肥胖是一种慢性疾病,需要有效的长期管理策略.
- 新的治疗目标对于改善肥胖治疗结果至关重要.
研究的目的:
- 评估survodutide的安全性,耐受性和有效性,这是一种双重葡萄糖和GLP-1受体激动剂,用于肥胖管理.
- 在第二阶段临床试验中确定顺丁的最佳剂量.
主要方法:
- 一个随机的,双盲的,安慰剂控制的,剂量查找的第二阶段试验.
- 在12个国家的43个中心注册了387名参与者 (BMI≥27 kg/m2).
- 参与者每周接受皮下注射苏尔沃杜提德 (0.6-4.8毫克) 或安慰剂,持续46周.
主要成果:
- 平均体重减轻范围从 -6.2%到 -14.9%的survodutide剂量,与 -2.8%与安慰剂在46周.
- 所有测试的伏丁胺剂量都被很好地容忍.
- 胃肠道不良事件是最常见的副作用.
结论:
- 苏尔沃杜提德在患有肥胖症的人群中显示出显著的,剂量依赖的体重减轻.
- 双重主动激素伏丁是肥胖管理的有前途的治疗候选者.
相关概念视频
Obesity
503
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
503
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
291
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
291
Drug Administration and Therapy Phases: Overview
466
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
466
Drugs for Treatment of Diarrhea-Predominant IBS
170
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
170
Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
Clinical Trials: Overview
2.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.9K


